PDE5 Inhibitor and Leucine Compositions for Metabolic Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic disorders, such as obesity and diabetes, are limited in effectiveness due to issues like low bioavailability and safety concerns with existing SIRT1 activators, and there is a need for safer and more comprehensive regulation of energy metabolism pathways.
Innovation Solution
Compositions combining PDE inhibitors, such as PDE5 inhibitors, with branched chain amino acids like leucine and its metabolites, which enhance energy metabolism by increasing fatty acid oxidation and mitochondrial biogenesis, thereby addressing metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SIRT1 activators like resveratrol are used to treat metabolic disorders, then energy metabolism regulation is improved, but bioavailability is limited and safety concerns arise due to high dosages required
Solution Approach 1:
The patent uses PDE5 inhibitors as intermediary compounds that activate the sirtuin pathway indirectly through the cGMP signaling pathway, rather than directly activating SIRT1. This intermediary mechanism allows for safer and more effective metabolic regulation at lower dosages, resolving the contradiction between treatment effectiveness and dosage safety
Solution Approach 2:
The patent changes the chemical parameter from direct SIRT1 activators (resveratrol) to PDE5 inhibitors (sildenafil, tadalafil, vardenafil), which have different pharmacokinetic properties including better bioavailability and lower required dosages, while still achieving the desired metabolic effect through pathway activation
2Power
If high dosages of SIRT1 activators are administered to overcome low bioavailability, then metabolic pathway activation is enhanced, but safety concerns increase
Solution Approach 1:
PDE5 inhibitors serve as safe intermediary agents that activate the sirtuin pathway through the cGMP signaling cascade, achieving strong metabolic pathway activation without the safety issues of high-dose direct SIRT1 activators
Solution Approach 2:
The patent copies the beneficial metabolic effects of caloric restriction and direct SIRT1 activation through an alternative pathway (cGMP-mediated sirtuin activation), achieving similar metabolic outcomes with safer compounds
3Adaptability or versatility
If existing treatments target specific energy metabolism pathways, then some metabolic effects are achieved, but comprehensive regulation of energy metabolism is limited
Solution Approach 1:
PDE5 inhibitors exhibit multi-functionality by simultaneously affecting multiple energy metabolism pathways including fatty acid oxidation, glucose metabolism, and mitochondrial function through sirtuin pathway activation, providing comprehensive metabolic regulation
Solution Approach 2:
The patent employs dynamic combination therapy where PDE5 inhibitors are combined with branched-chain amino acids, creating a flexible and adaptable treatment approach that can comprehensively regulate various aspects of energy metabolism
Data Source
AI summary
Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.